Global FLT3 Inhibitors Market
Global FLT3 Inhibitors Market Analysis Report 2022: A $2+ Billion Market by 2032 - Scope for Lucrative Opportunities in Emerging Markets
08 sept. 2022 07h03 HE | Research and Markets
Dublin, Sept. 08, 2022 (GLOBE NEWSWIRE) -- The "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and...
22157.jpg
Acute Myeloid Leukemia (AML) Market Insights & Epidemiology Analysis & Forecasts, 2018-2020 & 2021-2030: Major Markets, Marketed Therapies, Emerging Therapies, Case Reports, Patient Journey
05 août 2021 07h28 HE | Research and Markets
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML)- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. The...
22157.jpg
Global Acute Myeloid Leukemia (AML) Disease Analysis Report 2021: On Average, it Takes 10.8 Years from Phase I to Approval, Compared to 9.6 Years in the Overall Oncology Space
12 avr. 2021 06h48 HE | Research and Markets
Dublin, April 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous...
IVS_logo_20160331_CMYK.jpg
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
05 déc. 2019 06h00 HE | Invivoscribe, Inc.
SAN DIEGO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- For twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and...